Nassif Mikheal purchased $6K of NEOG (indirect holdings)

Nassif Mikheal (CEO) purchased 505 indirectly-held shares of NEOGEN CORP (NEOG) at $11.95 on 2026-10-09.

Original reporting
SEC EDGAR · Nassif Mikheal
Published Oct 9, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NEOG
Neutral
medium confidence
Mentioned
$NEOG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEOGNeutralLow
01

Why it matters

The filing provides a fresh, primary‑source data point on insider activity but the monetary size is minimal.

02

Market read

A small insider purchase with limited trading relevance; unlikely to affect price materially.

03

What to watch

If the CEO holds a larger undisclosed stake, this small buy might be part of a larger accumulation strategy.

Relevance 3/10Novelty 3/10Timing: same‑day filing

Background

Form 4 filings disclose insider trades and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$NEOGNeutralMedium confidence
Context

CEO Nassif Mikheal bought 505 shares of NEOG at $11.95 in an open‑market purchase filed on 2026‑10‑09.

Expected impact

minor upward pressure as the market prices in the insider buy

Evidence & confidence

The transaction is a primary Form 4 filing, but the amount is trivial relative to market cap, so any price effect is expected to be modest.

Market effects

No material impact on the broader biotech sector.

Limited to U.S. markets; no regional ripple.

Not globally relevant.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Neogen Corp

    US‑listed biotech firm (ticker NEOG).

  • Nassif Mikheal

    CEO of Neogen Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Neogen Chemicals Ltd (BOM:542665) (Q2 2027) Earnings Call Highlights: 42% Revenue

Neogen Chemicals (BOM:542665) reported Q2 2027 earnings, with a 42% revenue surge. The company guided FY27 battery chemicals revenue at INR 250-300 crore and FY28 at over INR 1,000 crore. Base chemicals guidance for FY27 was upgraded to over INR 1,100 crore. Net debt for FY28 is expected to be INR 1,300-1,500 crore. The company is benefiting from US demand shifts due to tax credits and has secured customer approvals for lithium electrolyte salts.

$NEOGHigh

Neogen Corporation announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva